From: A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis
Characteristics | Number of Cases | Percentage |
---|---|---|
Total Number | 38 | NA |
Gender | ||
 Male | 14 | 35.8% |
 Female | 24 | 63.2% |
Age ± SD (y) | 57.7 ± 13.2 | NA |
Cohort | ||
 Yale | 10 | 26.3% |
 Karolinska | 25 | 65.8% |
 Düsseldorf | 3 | 7.9% |
Tumor Size (cm) | ||
 Mean ± SD | 12.8 ± 4.4 | NA |
 Range | 5.5–21.0 | NA |
ENSAT 2008 Stage | ||
 I | 0 | 0.0% |
 II | 18 | 47.4% |
 III | 11 | 28.9% |
 IV | 9 | 23.7% |
Hormone Hypersecretion | ||
 Aldosterone | 1 | 2.6% |
 Cortisol | 9 | 23.7% |
 Androgen/DHEA | 4 | 10.5% |
 Estrogen | 1 | 2.6% |
 Multi-secretinga | 5 | 13.2% |
 Non-functional | 14 | 36.8% |
 No information available | 4 | 10.5% |
Outcome | ||
 Alive, no recurrence | 11 | 28.9% |
 Alive, recurrence | 5 | 13.2% |
 Death from disease | 16 | 42.1% |
 Death from other causes | 4 | 10.5% |
 Lost to follow-up | 2 | 5.3% |